Arrowhead Pharmaceuticals (ARWR) Accounts Payables (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Accounts Payables came in at $30.7 million in Q1 2026, up 208.09% YoY from $10.0 million in Q1 2025, and down 6.65% on a QoQ basis from $32.9 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Accounts Payables (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of Accounts Payables data on file, last reported at $30.7 million in Q1 2026.
- Quarterly Accounts Payables rose 208.09% year-over-year to $30.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.7 million (up 208.09% YoY) and the FY2025 annual result came in at $17.7 million, up 55.2% from the prior year.
- Accounts Payables retreated to $30.7 million in Q1 2026, from $32.9 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $35.9 million in Q3 2023 to a low of $796000.0 in Q4 2022.
- A 5-year average of $15.5 million and a median of $10.6 million in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables slumped 80.43% — and 2023, when it jumped 1150.56%.
- Tracing ARWR's Accounts Payables over 5 years: stood at $796000.0 in 2022, then soared by 460.3% to $4.5 million in 2023, then soared by 224.15% to $14.5 million in 2024, then soared by 127.83% to $32.9 million in 2025, then fell by 6.65% to $30.7 million in 2026.
- The last three Accounts Payables figures came in at $30.7 million (Q1 2026), $32.9 million (Q4 2025), and $17.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | 27.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.78 Mn |
| Mar 31, 2026 | 30.75 Mn |
| Dec 31, 2025 | 32.94 Mn |
| Sep 30, 2025 | 17.67 Mn |
| Jun 30, 2025 | 33.05 Mn |
| Mar 31, 2025 | 9.98 Mn |
| Dec 31, 2024 | 14.46 Mn |
| Sep 30, 2024 | 11.39 Mn |
| Jun 30, 2024 | 26.55 Mn |
| Mar 31, 2024 | 8.52 Mn |
| Dec 31, 2023 | 4.46 Mn |
| Sep 30, 2023 | 35.87 Mn |
| Jun 30, 2023 | 7.87 Mn |
| Mar 31, 2023 | 9.56 Mn |
| Dec 31, 2022 | 796,000.00 |
| Sep 30, 2022 | 2.87 Mn |
| Jun 30, 2022 | 5.89 Mn |
| Mar 31, 2022 | 10.60 Mn |
| Dec 31, 2021 | 4.07 Mn |
| Sep 30, 2021 | 9.46 Mn |